ENTO enterothera.com Gross Profit Margin

Official company branding of Entero Therapeutics, Inc. (ENTO)

Entero Therapeutics, Inc. (ENTO) price volatility is driven by its expansion into the rare GI pathology segment to capture market share. Gross margins demonstrate profit resilience after deducting expenses, where the value of 0.00 serves as the current metric. Stabilization is expected through the establishment of a gastroenterology therapeutic center, although revenue deficits and clinical trial costs are creating temporary cash flow pressure.

ENTO (enterothera.com) Return on Gross Profit history from 05/18/2024 to 12/01/2025

Financial and market metric breakdowns for enterothera.com (ENTO)

- stock price and consensus target price:
Basic company analysis:Entero Therapeutics, Inc. (ENTO)
Manufactured products of Entero Therapeutics, Inc.

The operational stability of Entero Therapeutics, Inc. (ENTO) depends on its ability to control direct costs amid market volatility. The current restructuring of the R&D pipeline and the transition of research into asset valuation mode are temporarily reducing production activity. By analyzing the current gross margin, an investor assesses the portion of revenue net of cost of goods sold, which helps identify hidden cost dependencies on price and recognize the risk of future drawdowns.